| Literature DB >> 35947581 |
Jacobeth T Kganakga1, Petra Bester1, Cristian Ricci1, Shani Botha-Le Roux2, Marike Cockeran3, Minrie Greeff1, Iolanthé M Kruger1.
Abstract
BACKGROUND: Cardiovascular diseases (CVDs) are increasing at an alarming rate among the South African population. This study aimed to determine the prognostic value of modifiable CVD risk factors for fatal and non-fatal events to inform cardiovascular health promotion practices in the South African public health system.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35947581 PMCID: PMC9365156 DOI: 10.1371/journal.pone.0271169
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Baseline demographic characteristics of study participants.
| No CVD outcomes N = 1,918 | Non-fatal CVD outcomes N = 69 | Fatal CVD outcomes N = 25 | Pvalue | ||
|---|---|---|---|---|---|
| Age | 47.81(41.62–55.73) | 57.12(48.93–65.68) | 60.43(50.34–65.90) |
| |
|
| |||||
| Men | 37.0 | 36.2 | 52.0 |
| |
| Women | 63.0 | 63.8 | 48.0 |
| |
|
| |||||
| Urban (%) | 49.5 | 65.2 | 44.0 |
| |
| Rural (%) | 50.5 | 34.8 | 56.0 |
| |
| Formal educ (%) | 62.9 | 30.4 | 64.0 |
| |
| HIV positive (%) | 16.6 | 11.6 | 4.2 |
| |
|
| |||||
| Current tobacco (%) | 51.8 | 53.6 | 52.0 |
| |
| Current alcohol (%) | 39.2 | 46.4 | 36.0 |
| |
| GGT (U/l) | 45.15(29.35–85.00) | 48.29(31.34–94.51) | 73.82(46.00–173.00) |
| |
| WPA index | 2.87(2.54–3.23) | 2.64(2.28–2.90) | 2.66(2.42–2.92) |
| |
|
| |||||
| Waist circum. (cm) | 77.25(70.20–87.80) | 80.18(70.04–87.43) | 74.88(64.53–84.74) |
| |
| Hip circum. (cm) | 93.20(84.90–106.1) | 93.48(84.75–104.9) | 86.85(76.33–98.28) |
| |
| Waist: hip ratio | 0.83 (0.78–0.88) | 0.85(0.80–0.90) | 0.86 (0.80–0.91) |
| |
| BMI (kg/m2) | 22.98(19.31–28.96) | 23.53(19.33–28.64) | 21.27(16.00–25.51) |
| |
|
| |||||
| SBP (mmHg) | 129 (116–146) | 144 (130–171) | 127 (106–150) |
| |
| DBP (mmHg) | 87 (77–96) | 94 (87–108) | 80 (72–93) |
| |
| MAP (mmHg) | 100 (91–120) | 110 (100–132) | 96 (87–111) |
| |
| BP medication (%) | 7.3 | 17.4 | 12.5 |
| |
| Framingham score | 5.0 (3.0–8.0) | 10.0 (4.0–16.0) | 7.0 (2.5–10.0) |
| |
|
| |||||
| Glucose (mmol/l) | 4.80 (4.30–5.30) | 4.90 (4.00–5.50) | 5.00 (4.45–5.35) |
| |
| HbA1c (%) | 5.50 (5.30–5.80) | 5.50 (5.20–5.95) | 5.40 (5.03–5.98) |
| |
| Diabetic (%) | 5.2 | 9.7 | 4.8 |
| |
|
| |||||
| HDL (mmol/l) | 1.41 (1.07–1.87) | 1.44 (1.00–1.82) | 1.61 (1.22–2.25) |
| |
| LDL (mmol/l) | 2.77 (2.07–3.64) | 2.91 (2.07–3.51) | 2.72 (1.71–3.70) |
| |
| Trig (mmol/l) | 1.07 (0.82–1.54) | 1.21 (0.88–1.67) | 1.06 (0.80–1.49) |
| |
| Total chol. (mmol/l) | 4.81 (3.40–5.87) | 4.98 (4.33–5.98) | 4.54 (3.83–6.51) |
| |
| Trig:HDL | 0.78 (0.49–1.25) | 0.83 (0.55–1.35) | 0.62 (0.46–1.21) |
| |
Two-tailed hypotheses, z-test and p-values, were calculated between the three groups; only the lowest p-trend was reported between-group differences. Continuous variables reported using median and the range between first quatile and third quartile (Interquartile range Q1-Q3).
NS: not significant; HIV: Human immunodeficiency virus; GGT: gamma-glutamyltransferase; WPA index: weighted physical activity index; HbA1c: Glycated haemoglobin; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; Trig: triglycerides
* Fasting plasma glucose
Point-biserial correlations with 95% confidence limits between CVD outcomes and sample’s features.
| Non-fatal CVD outcomes | Fatal CVD outcomes | |||
|---|---|---|---|---|
| rpb (95% CI) | Pvalue | rpb (95% CI) | Pvalue | |
| Age | .126 (.083, .169) |
| .099 (.056, .143) |
|
| BMI (kg/m2) | .004 (-.040, .047) |
| .006 (-.006, .010) |
|
| WPA-index | -.097 (-.141, -.053) |
| -.045 (-.089, .000) |
|
| FRS | .107 (.064, .150) |
| .021 (-.023, .065) |
|
| SBP (mmHg) | .115 (.072, .158) |
| -.010 (-.054, .034) |
|
| DBP (mmHg) | .098 (.055, .142) |
| -.030 (-.074, .014) |
|
| GGT (U/l) | .014 (-.031, .060) |
| .067 (.022, .112) |
|
| Fasting glucose (mmol/l) | .004 (-.042, .050) |
| .009 (-.037, .054) |
|
| HbA1c (%) | .005 (-.040, .049) |
| -.026 (-.070, .019) |
|
| Total chol. (mmol/l) | .015 (-.030, .060) |
| -.001 (-.046, .044) |
|
| Trig (mmol/l) | .040 (-.005, .085) |
| -.003 (-.049, .042) |
|
CVD: Cardiovascular disease; BMI: Body Mass Index; WPA: Weighted Physical Activity Index; FRS: Framingham Risk Score; SBP: Systolic Blood Pression; DBP: Dyastolic Blood Pression; GGT: Gamma Glutamyltransferase; HbA1c: Glycated Haemoglobin; Total chol.: Total Cholesterol; Trig: Total Tryglicerides; NS: Not significant
* Fasting plasma glucose
Odds ratios (OR) and 95% confidence intervals (95% CI) of sample‘s features in relation to non-fatal and fatal cardiovascolar outcomes.
| Non-fatal CVD outcomes | Fatal CVD outcomes | |||
|---|---|---|---|---|
| OR (95% CI) | Pvalue | OR (95% CI) | Pvalue | |
| Age (5 year increase) | 1.87 (1.29, 2.71) |
| 3.21 (1.86, 5.55) |
|
| Sex (Men vs. Women) | 0.68 (0.34, 1.36) |
| 1.41 (0.41, 4.85) |
|
| Location (Urban vs. Rural) | 0.92 (0.48, 1.75) |
| 1.03 (0.33, 3.23) |
|
| Education (Any vs. None) | 0.55 (0.28, 1.09) |
| 1.76 (0.59, 5.31) |
|
| BMI <18.5 vs. BMI 18.5–25 | 0.88 (0.38, 2.04) |
| 1.65 (0.53, 5.16) |
|
| BMI 25–30 vs. BMI 18.5–25 | 0.79 (0.34, 1.80) |
| 0.37 (0.04, 3.21) |
|
| BMI ≥ 30 vs. BMI 18.5–25 | 0.85 (0.38, 1.90) |
| 0.32 (0.03, 3.10) |
|
| WPA (+ 1 STD) | 0.62 (0.46, 0.83) |
| 0.85 (0.50, 1.45) |
|
| FRS (+ 1 STD) | 1.35 (0.90, 2.01) |
| 0.49 (0.23, 1.03) |
|
| S/A-YY vs. S/A-NN | 1.62 (0.75, 3.54) |
| 0.40 (0.11, 1.49) |
|
| S/A-YN vs. S/A-NN | 1.02 (0.43, 2.41) |
| 1.29 (0.28, 5.95) |
|
| S/A-NY vs. S/A-NN | 1.10 (0.37, 3.29) |
| 0.70 (0.12, 4.08) |
|
| Hypertension (Yes vs. No) | 2.47 (1.26, 4.85) |
| 0.38 (0.11, 1.27) |
|
| GGT (+ 1 STD) | 0.89 (0.65, 1.21) |
| 2.45 (1.36, 4.42) |
|
| FGL (+ 1 STD) | 0.89 (0.68, 1.17) |
| 1.25 (0.70, 2.24) |
|
| GHB (+ 1 STD) | 0.82 (0.62, 1.09) |
| 0.60 (0.34, 1.04) |
|
| TCH (+ 1 STD) | 0.75 (0.55, 1.03) |
| 1.01 (0.56, 1.82) |
|
| TGL (+ 1 STD) | 1.10 (0.79, 1.53) |
| 0.96 (0.50, 1.83) |
|
CVD: Cardiovascular disease; OR: Mutually adjusted Odds Ratio; BMI: Body Mass Index; WPA: Weighted Physical Activity Index; FRS: Framingham Risk Score; S/A: Smoking and alcohol; Y: Yes; N: No; GGT: Gamma Glutamyl Transferase; FGL: Fasting Glucose; GHB: Glycated Haemoglobin; TCH: Total Cholesterol; TGL: Total tryglicerides.
Fig 1ROC curve of risk factors related to all, non-fatal and fatal CV outcomes.
M0 (panels A and D): model of age, sex, locality and education; M1 (panels B and E): M0 supplementary adjusted for lifestyle (merged current smoking and alcohol use and weighted physical activity index); M2 (panels C and F): M1 supplementary adjusted for CVD risk factors (Framingham risk score and hypertension) and biochemical profile.
Fig 2ROC curve of risk factors related to non-fatal and fatal CV outcomes.
HYP: Hypertension, WPA: Weighted Physical Activity Index, GGT: Gamma-glutamyl-transferase.